AR132992A1 - Agonistas de trem2 - Google Patents

Agonistas de trem2

Info

Publication number
AR132992A1
AR132992A1 ARP240101553A ARP240101553A AR132992A1 AR 132992 A1 AR132992 A1 AR 132992A1 AR P240101553 A ARP240101553 A AR P240101553A AR P240101553 A ARP240101553 A AR P240101553A AR 132992 A1 AR132992 A1 AR 132992A1
Authority
AR
Argentina
Prior art keywords
trem2
agonists
compounds
diseases
prevention
Prior art date
Application number
ARP240101553A
Other languages
English (en)
Inventor
Stefan Berchtold
Virginie Brom
Julie Charpentier
Francesco Maria Emilia Di
Guido Galley
Luca Claudio Gobbi
Wolfgang Guba
Roland Johann Humm
Marie Imhoff
- Ohara Fionn Susannah Paule
Anglique Patiny-Adam
Flore Marie Aude Reggiani
Nicolas Zeidan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132992A1 publication Critical patent/AR132992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona compuestos que tienen la fórmula general (1) en donde A¹, A², X¹, X², R¹, R², R³, R⁴ y R⁷ son como se describen en la presente, composiciones que incluyen los compuestos, procesos para elaborar los compuestos y métodos para usar los compuestos en el tratamiento o la prevención de enfermedades que están asociadas con TREM2.
ARP240101553A 2023-06-19 2024-06-18 Agonistas de trem2 AR132992A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23179957 2023-06-19
EP23211237 2023-11-21

Publications (1)

Publication Number Publication Date
AR132992A1 true AR132992A1 (es) 2025-08-13

Family

ID=91621082

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101553A AR132992A1 (es) 2023-06-19 2024-06-18 Agonistas de trem2

Country Status (14)

Country Link
EP (1) EP4727934A1 (es)
JP (1) JP2026521750A (es)
KR (1) KR20260023587A (es)
CN (1) CN121335893A (es)
AR (1) AR132992A1 (es)
AU (1) AU2024312352A1 (es)
CL (1) CL2025004002A1 (es)
CO (1) CO2025018165A2 (es)
CR (1) CR20250537A (es)
IL (1) IL324897A (es)
MX (1) MX2025015264A (es)
PE (1) PE20260310A1 (es)
TW (1) TW202515878A (es)
WO (1) WO2024260929A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025206254A1 (en) 2024-01-04 2026-06-11 Muna Therapeutics Aps Trem2 modulators
IL328677A (en) 2024-01-04 2026-07-01 Muna Therapeutics Aps 2-Azatidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-8,7-dihydropyrimido[4,5-D]pyrimidine derivatives as TREM2 modulators for the treatment of neurodegenerative diseases
WO2026077861A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists
WO2026115009A1 (en) * 2024-11-29 2026-06-04 F. Hoffmann-La Roche Ag Trem2 agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE

Also Published As

Publication number Publication date
CL2025004002A1 (es) 2026-04-06
WO2024260929A1 (en) 2024-12-26
CO2025018165A2 (es) 2026-01-23
EP4727934A1 (en) 2026-04-22
MX2025015264A (es) 2026-02-03
TW202515878A (zh) 2025-04-16
JP2026521750A (ja) 2026-07-01
IL324897A (en) 2026-01-01
AU2024312352A1 (en) 2025-12-11
PE20260310A1 (es) 2026-02-11
CN121335893A (zh) 2026-01-13
CR20250537A (es) 2026-01-19
KR20260023587A (ko) 2026-02-20

Similar Documents

Publication Publication Date Title
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
PH12021551065A1 (en) Fused ring compounds
PH12021500014A1 (en) Fused ring compounds
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
UY37656A (es) Compuestos que inhiben la proteína mcl-1
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
CU24564B1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
BR112022005627A2 (pt) Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto
CO2025018165A2 (es) Agonistas de trem2
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY39881A (es) “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS”
PY1986693A (es) Compuestos herbicidas
AR134046A1 (es) Inhibidores de cbl-b y métodos de uso de los mismos
AR134419A1 (es) Compuestos que inhiben la quinasa tipo polo 4
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento